However, a recent meta-analysis of 15 studies including different cancers indicated that LAG-3 expression was associated with better OS (HR = 0.81, 95% CI: 0.66–0.99, p = 0.04), with a greater magnitude in early-stage malignancies (HR = 0.73, 95% CI: 0.60–0.88) and an improved DFS in breast cancer in a subgroup analysis (HR = 0.64, 95% CI: 0.42–0.98) [40]. Here, LAG3 is linked to breast cancer.